The Kaiser Permanente (KP) Oncology Clinical Trials programs of KP Northern California, Southern California, Northwest, Colorado, and Hawaii are applying to become a Community Site in the NCI Community Oncology Research Program (NCORP). The overarching goal of the KP NCORP Community Site application is to bring the benefits of medical advances to our racially and ethnically diverse membership and to the community at large by increasing clinical trial access/accrual and by conducting cancer care delivery research (CCDR).
Our specific aims are as follows: 1) Enhance enrollment in clinical trials of cancer prevention, control, screening, treatment, and imaging, and in ancillary studies of health-related quality of life and patient-reported outcomes;2) Conduct CCDR and participate in shaping the NCORP's emerging CCDR agenda;and, 3) Conduct studies and assist the research bases in cancer disparities research. The KP components in this application have a robust history of high enrollment to NCI clinical trials. KP's diverse membership (>30% minority) Will contribute to NCORP's enrollment of large numbers of older and minority participants that reflect the demographic distribution of the US cancer burden. The KP Cancer Care Programs also represent a rapidly growing model of health care delivery that is being emulated throughout the US. KP's fully integrated delivery systems provide an ideal platform for clinical trials and CCDR, made even more attractive by the presence of cancer researchers from five distinct but interconnected research groups who are deeply embedded in the systems that they serve. The KP NCORP will work through multiple NCI-designated NCORP research bases to assist in development and execution of clinical trials and CCDR. By joining the National Clinical Trial Network as an NCORP Community Site, we believe the KP Oncology Clinical Trials program and our KP research centers can make important contributions to clinical trials and to CCDR, as well as accelerate the translation of knowledge from clinical trials into clinical practice and results of CCDR into best practices for healthcare systems and organizations.
As part of NCORP's integrated network of community organizations and research bases, the goal of the KP NCORP Community Site is to bring medical advances to our membership and the community at large by increasing clinical trial access/accrual and by conducting cancer care delivery research. KP's integrated health plan is an ideal platform for accelerating the translation of findings into clinical practice.
|West, Howard L; Moon, James; Wozniak, Antoinette J et al. (2018) Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer 19:84-92|
|Henry, N Lynn; Unger, Joseph M; Schott, Anne F et al. (2018) Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. J Clin Oncol 36:326-332|
|Persky, Daniel O; Li, Hongli; Rimsza, Lisa M et al. (2018) A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. Am J Hematol 93:486-493|
|Flaig, Thomas W; Plets, Melissa; Hussain, Maha H A et al. (2017) Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction. JAMA Oncol 3:e170231|
|Yao, James C; Guthrie, Katherine A; Moran, Cesar et al. (2017) Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. J Clin Oncol 35:1695-1703|
|Chung, Vincent; McDonough, Shannon; Philip, Philip A et al. (2017) Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial. JAMA Oncol 3:516-522|
|Sekeres, Mikkael A; Othus, Megan; List, Alan F et al. (2017) Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol 35:2745-2753|
|Danilov, Alexey V; Li, Hongli; Press, Oliver W et al. (2017) Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial. Leuk Lymphoma 58:461-465|
|Chen, Robert W; Li, Hongli; Bernstein, Steven H et al. (2017) RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. Br J Haematol 176:759-769|
|Durie, Brian G M; Hoering, Antje; Abidi, Muneer H et al. (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389:519-527|
Showing the most recent 10 out of 12 publications